Ocular Delivery of Peptides and Proteins

Peptide and Protein Delivery

Volumn , Issue , 2011, Pages 87-103

  Vyas, Suresh P ^a   Paliwal, Rishi ^a   Paliwal, Shivani Rai ^a  

^a DR H S GOUR UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882533962     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-384935-9.10005-7     Document Type: Chapter

References (49)

1. S. Wadhwa, R. Paliwal, S.R. Paliwal and S.P. Vyas (2009) Nanocarriers in ocular drug delivery: An update review. Curr. Pharm. Des. 15 2724-2750.
2. V.H.L. Lee (1987) Ophthalmic delivery of peptides and proteins. Pharm. Technol. 11 26-38.
3. J.W. Shell (1984) Ophthalmic drug delivery systems. Surv. Ophthalmol. 29 117-128.
4. V.H. Lee and J.R. Robinson (1986) Topical ocular drug delivery: Recent developments and future challenges. J. Ocul. Pharmacol. 2 67-108.
5. S.P. Vyas, N. Mysore, V. Jaitely and N. Venkatesan (1998) Discoidal niosome based controlled ocular delivery of timolol maleate. Pharmazie 53 466-469.
6. S.P. Vyas, S. Ramchandraiah, C.P. Jain and S.K. Jain (1992) Polymeric pseudolatices bearing pilocarpine for controlled ocular delivery. J. Microencapsul. 9 347-355.
7. S.K. Sahoo, F. Dilnawaz and S. Krishnakumar (2008) Nanotechnology in ocular drug delivery. Drug Discov. Today 13 144-151.
8. J. Vandervoort and A. Ludwig (2007) Ocular drug delivery: Nanomedicine applications. Nanomedicine 2 11-21.
9. C.W. Oyster (1999) The Human Eye: Structure and Function. Sunderland, MA, USA: Sinauer Associates
10. G.H. Cassel, M.D. Billig, H.G. Randall and M.F. Goldberg (1998) The Eye Book: A Complete Guide to Eye Disorders and Health. Maryland, USA: Johns Hopkins Press
11. R.E. Stratford and V.H.L. Lee (1995) Ocular aminopeptidase activity and distribution in the albino rabbit. Curr. Eye Res. 4 995-1000.
12. R.J. Erb, L.M. Her, A. Abdallah and A.K. Mitra (1991) Pharmacodynamics and biophasic drug levels of methionine enkephalin. Pharm. Res. 8 930-932.
13. S. Duvvuri, S. Majumdar and A.K. Mitra (2003) Drug delivery to the retina: Challenges and opportunities. Expert Opin. Biol. Ther. 3 45-56.
14. R.D. Schoenwald (1990) Ocular drug delivery. Pharmacokinetic considerations. Clin. Pharmacokinet. 18 255-269.
15. G.C. Chiou (1994) Systemic delivery of polypeptide drugs through ocular route. J. Ocul. Pharmacol. 10 93-99.
16. V.H. Lee (1990) New directions in the optimization of ocular drug delivery. J. Ocul. Pharmacol. 6 157-164.
17. G.C. Chiou and Y.C. Ching (1989) Improvement of systemic absorption of insulin through the eyes with absorption enhancers. J. Pharm. Sci. 78 815-818.
18. A. Yamamoto, A.M. Luo, S. Dodda-Kashi and V.H. Lee (1989) The ocular route for systemic insulin delivery in the albino rabbit. J. Pharmacol. Exp. Ther. 249 249-255.
19. Y.C. Lee, P. Simamora and S.H. Yalkowsky (1997) Effect of Brij-78 on systemic delivery of insulin from an ocular device. J. Pharm. Sci. 86 430-433.
20. E. Hayakawa, D.S. Chien, K. Inagaki, A. Yamamoto, W. Wang and V.H. Lee (1992) Conjunctival penetration of insulin and peptide drugs in the albino rabbit. Pharm. Res. 9 769-775.
21. R. Gaudana, J. Jwala, S.H. Boddu and A.K. Mitra (2009) Recent perspectives in ocular drug delivery. Pharm. Res. 26 1197-1216.
22. V. Ganapathyand and F.H. Leibach (1982) Peptide transport in intestinal and renal brush border membrane vesicles. Life Sci. 30 2137-2146.
23. R.S. Talluri, S.K. Samanta, R. Gaudana and A.K. Mitra (2008) Synthesis, metabolism and cellular permeability of enzymatically stable dipeptide prodrugs of acyclovir. Int. J. Pharm. 361 118-124.
24. S.M. Ocheltree, R.F. Keep, H. Shen, D. Yang, B.A. Hughes and D.E. Smith (2003) Preliminary investigation into the expression of proton-coupled oligopeptide transporters in neural retina and retinal pigment epithelium (RPE): Lack of functional activity in RPE plasma membranes. Pharm. Res. 20 1364-1372.
25. H. Atluri, B.S. Anand, J. Patel and A.K. Mitra (2004) Mechanism of a model dipeptide transport across blood–ocular barriers following systemic administration. Exp. Eye Res. 78 815-822.
26. C. Dias, Y. Nashed, H. Atluri and A. Mitra (2002) Ocular penetration of acyclovir and its peptide prodrugs valacyclovir and val-valacyclovir following systemic administration in rabbits: An evaluation using ocular microdialysis and lc-ms. Curr. Eye Res. 25 243-252.
27. A. Hussain and J.E. Truelove (1976) Prodrug approaches to enhancement of physicochemical properties of drugs IV: Novel epinephrine prodrug. J. Pharm. Sci. 65 1510-1512.
28. S. Wadhwa, R. Paliwal, S.R. Paliwal and S.P. Vyas (2009) Chitosan and its role in ocular therapeutics. Mini Rev. Med. Chem. 9 1639-1647.
29. S. Wadhwa, R. Paliwal, S.R. Paliwal and S.P. Vyas (2010) Hyaluronic acid modified chitosan nanoparticles for effective management of glaucoma: Development, characterization, and evaluation. J. Drug Target. 18 292-302.
30. A.M. De Campos, A. Sánchez and M.J. Alonso (2001) Chitosan nanoparticles: A new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. Int. J. Pharm. 224 159-168.
31. R. Srinivasan and S.K. Jain (1998) Insulin delivery through the ocular route. Drug Deliv. 5 53-55.
32. U. Pleyer, B. Elkins, D. Rückert, S. Lutz, J. Grammer, J. Chou, K.H. Schmidt and B.J. Mondino (1994) Ocular absorption of cyclosporine A from liposomes incorporated into collagen shields. Curr. Eye Res. 13 177-181.
33. E.H. Gokce, G. Sandri, M.C. Bonferoni, S. Rossi, F. Ferrari, T. Güneri, et al. (2008) Cyclosporine A loaded SLNs: Evaluation of cellular uptake and corneal cytotoxicity. Int. J. Pharm. 364 76-86.
34. E.H. Gökçe, G. Sandri, S. Eğrilmez, M.C. Bonferoni, T. Güneri and C. Caramella (2009) Cyclosporine a-loaded solid lipid nanoparticles: Ocular tolerance and in vivo drug release in rabbit eyes. Curr. Eye Res. 34 996-1003.
35. I. Yenice, M.C. Mocan, E. Palaska, A. Bochot, E. Bilensoy, I. Vural, et al. (2008) Hyaluronic acid coated poly-epsilon-caprolactone nanospheres deliver high concentrations of cyclosporine A into the cornea. Exp. Eye Res. 87 162-167.
36. L. Lajavardi, S. Camelo, F. Agnely, W. Luo, B. Goldenberg, M.C. Naud, et al. (2009) New formulation of vasoactive intestinal peptide using liposomes in hyaluronic acid gel for uveitis. J. Control. Release 139 22-30.
37. S.P. Vyas and R.K. Khar (2008) Ocular drug delivery systems. Controlled Drug Delivery: Concepts and Advances Delhi, India: Vallabh Prakashan
38. V.H.L. Lee, L.W. Carson and K.A. Takemoto (1986) Macromolecular drug absorption in the albino rabbit eye. Int. J. Pharm. 29 43-51.
39. C. Newton, B.M. Gebhardt and H.E. Kaufman (1988) Topically applied cyclosporine in zone prolongs corneal allograft survival. Invest. Ophthalmol. Vis. Sci. 29 208-215.
40. K. Morimoto, T. Nakai and K. Morisaka (1987) Evaluation of permeability enhancement of hydrophilic compounds and macromolecular compounds by bile salts through rabbit corneas in vitro. J. Pharm. Pharmacol. 39 124-126.
41. P. Chetoni, S. Burgalassi, D. Monti and M.F. Saettone (2003) Ocular toxicity of some corneal penetration enhancers evaluated by electrophysiology measurements on isolated rabbit corneas. Toxicol. Vitro 17 497-504.
42. Y. Wang, H. Lin, S. Lin, J. Qu, J. Xiao, Y. Huang, et al. (2010) Cell-penetrating peptide TAT-mediated delivery of acidic FGF to retina and protection against ischemia-reperfusion injury in rats. J. Cell. Mol. Med. 14 1998-2005.
43. M. Abrishami, S.Z. Ganavati, D. Soroush, M. Rouhbakhsh, M.R. Jaafari and B. Malaekeh-Nikouei (2009) Preparation, characterization, and in vivo evaluation of nanoliposomes-encapsulated bevacizumab (avastin) for intravitreal administration. Retin.-J. Retin. Vitr. Dis. 29 699-703.
44. J. Ambati, E.S. Gragoudas, J.W. Miller, T.T. You, K. Miyamoto, F.C. Delori, et al. (2000) Transscleral delivery of bioactive protein to the choroid and retina. Invest. Ophthalmol. Vis. Sci. 41 1186-1191.
45. E. Gavini, P. Chetoni, M. Cossu, M.G. Alvarez, M.F. Saettone and P. Giunchedi (2004) PLGA microspheres for the ocular delivery of a peptide drug, vancomycin using emulsification/spray-drying as the preparation method: In vitro/in vivo studies. Eur. J. Pharm. Biopharm. 57 207-212.
46. S. Majumdar, V. Kansara and A.K. Mitra (2006) Vitreal pharmacokinetics of dipeptide monoester prodrugs of ganciclovir. J. Ocul. Pharmacol. Ther. 22 231-241.
47. L. Lajavardi, A. Bochot, S. Camelo, B. Goldenberg, M.C. Naud, F. Behar-Cohen, et al. (2007) Downregulation of endotoxin-induced uveitis by intravitreal injection of vasoactive intestinal Peptide encapsulated in liposomes. Invest. Ophthalmol. Vis. Sci. 48 3230-3238.
48. S. Camelo, L. Lajavardi, A. Bochot, B. Goldenberg, M.C. Naud, E. Fattal, et al. (2007) Ocular and systemic bio-distribution of rhodamine-conjugated liposomes loaded with VIP injected into the vitreous of Lewis rats. Mol. Vis. 13 2263-2274.
49. K. Patel, S. Trivedi, S. Luo, X. Zhu, D. Pal, E.R. Kern, et al. (2005) Synthesis, physicochemical properties and antiviral activities of ester prodrugs of ganciclovir. Int. J. Pharm. 305 75-89.